US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% MSTR $160.01 ▲+0.00%
FinancialContent

MeiraGTx Holdings plc - Ordinary Shares (NQ:MGTX)

10.79 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MeiraGTx Holdings plc - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
From MeiraGTx
Via GlobeNewswire
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
One of J&J's investments stands head-and-shoulders above the rest. 
Via The Motley Fool
MeiraGTx (NASDAQ:MGTX) Clears Minervini Trend Template and High-Growth Momentum Screen ↗
Via Chartmill
News headline image
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
MeiraGTx Holdings (NASDAQ:MGTX) Passes Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle? ↗
Via Stocktwits
News headline image
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MeiraGTx
Via GlobeNewswire
News headline image
What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near ↗
Stuart Naylor's 4% portfolio reduction follows an 89% one-year stock surge, executed under a pre-scheduled Rule 10b5-1 trading plan adopted in December 2025. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Via Investor Brand Network
Topics Intellectual Property
News headline image
The Biotech Tug-of-War: Is Kiora Pharmaceuticals Positioned to Ride the 2025 Commodity Wave?
As of December 18, 2025, the financial landscape is defined by a stark divergence in the commodities market, creating a complex environment for clinical-stage biotechnology firms. While gold prices... 
Via MarketMinute
Topics Derivatives Economy Intellectual Property
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
From BioMedWire
Via GlobeNewswire
News headline image
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration ↗
MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children with LCA4. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms 
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Sales Jump 1,133 Percent ↗
Via The Motley Fool
News headline image
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy 
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
From MeiraGTx
Via GlobeNewswire
< Previous 1 2 3 4 Next >